Temazepam 20mg remains one of the most commonly prescribed and trusted short-to-intermediate acting benzodiazepines in 2026 for the short-term management of severe insomnia, particularly when difficulty falling asleep, frequent awakenings, or early morning waking severely impairs daytime functioning. Approved in most developed markets since the late 1970s and early 1980s, temazepam belongs to the benzodiazepine […]
In 2026, Temazepam 20mg remains a widely recognized short-to-intermediate-acting benzodiazepine primarily prescribed for the short-term treatment of severe insomnia characterized by difficulty falling asleep, frequent awakenings, or early-morning waking. Marketed under brand names such as Restoril in some regions, this medication enhances GABA activity in the brain to produce sedative, anxiolytic, and muscle-relaxant effects, helping […]